While iniparib showed early promise, it failed clinical trials in a number of malignancies including ovarian cancer, triple-negative breast cancer, squamous non–small-cell lung cancer and others, it was structurally different to other PARPis under development and was shown not to inhibit PARP at clinically relevant doses [99,100]. Here, PARP1 is linked to ovarian carcinoma.